Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 1230-1232, March 15, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cairns, P.
Right arrow Articles by Knowles, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cairns, P.
Right arrow Articles by Knowles, M. A.

Preliminary Mapping of the Deleted Region of Chromosome 9 in Bladder Cancer

Paul Cairns1, Margaret E. Shaw and Margaret A. Knowles

Epithelial Carcinogenesis Laboratory, Marie Curie Research Institute, The Chart, Oxted, Surrey, RH8 OTL, United Kingdom

Inactivation of a suppressor gene by deletion of chromosome 9 is a candidate initiating event in bladder carcinogenesis. We have used 13 polymorphic markers spanning the length of chromosome 9 in order to map the region of deletion in human bladder carcinomas. In the majority of tumors loss of heterozygosity was found at all informative sites along the chromosome, indicating deletion of the entire chromosome. Nine tumors had selective deletions of chromosome 9. Mapping of the deleted region in these tumors suggests that the target gene is located between D9S22 at 9q22 and D9S18 at 9p12–13.

1 To whom requests for reprints should be addressed.

Received 1/21/93. Accepted 2/ 2/93.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E. J. Chapman, P. Harnden, P. Chambers, C. Johnston, and M. A. Knowles
Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype
Clin. Cancer Res., August 15, 2005; 11(16): 5740 - 5747.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
J. S. Aveyard and M. A. Knowles
Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification
J. Mol. Diagn., November 1, 2004; 6(4): 356 - 365.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky
Genome-Wide Genetic Characterization of Bladder Cancer: A Comparison of High-Density Single-Nucleotide Polymorphism Arrays and PCR-based Microsatellite Analysis
Cancer Res., May 1, 2003; 63(9): 2216 - 2222.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Berggren, R. Kumar, S. Sakano, L. Hemminki, T. Wada, G. Steineck, J. Adolfsson, P. Larsson, U. Norming, H. Wijkstrom, et al.
Detecting Homozygous Deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) Gene in Urinary Bladder Cancer Using Real-Time Quantitative PCR
Clin. Cancer Res., January 1, 2003; 9(1): 235 - 242.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
R. Baffa, L. G. Gomella, A. Vecchione, P. Bassi, K. Mimori, J. Sedor, C. M. Calviello, M. Gardiman, C. Minimo, S. E. Strup, et al.
Loss of FHIT Expression in Transitional Cell Carcinoma of the Urinary Bladder
Am. J. Pathol., February 1, 2000; 156(2): 419 - 424.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Zhao, J. Richter, U. Wagner, B. Roth, P. Schraml, T. Zellweger, D. Ackermann, U. Schmid, H. Moch, M. J. Mihatsch, et al.
Chromosomal Imbalances in Noninvasive Papillary Bladder Neoplasms (pTa)
Cancer Res., September 1, 1999; 59(18): 4658 - 4661.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Morimura, S. Yamamoto, T. Murai, S. Mori, T.-X. Chen, H. Wanibuchi, and S. Fukushima
LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine
Carcinogenesis, April 1, 1999; 20(4): 715 - 718.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
C A Reznikoff, C Belair, E Savelieva, Y Zhai, K Pfeifer, T Yeager, K J Thompson, S DeVries, C Bindley, and M A Newton
Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells.
Genes & Dev., September 15, 1994; 8(18): 2227 - 2240.
[Abstract] [PDF]


Home page
ScienceHome page
P Cairns, L Mao, A Merlo, D. Lee, D Schwab, Y Eby, K Tokino, P van der Riet, J. Blaugrund, and D Sidransky
Rates of p16 (MTS1) mutations in primary tumors with 9p loss
Science, July 15, 1994; 265(5170): 415 - 417.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.